Brand, Generic Companies Excluding Side Deals In Reverse Settlements
Executive Summary
Brand name and generic drug manufacturers are no longer routinely attaching side deals to their patent infringement settlement agreements, the Federal Trade Commission reports in its annual summary of these deals